The proliferation of tongue cancer cells is inhibited upon Med19 shRNA treatment. (a) Growth curve by MTT assay. Cells were treated with negative control shRNA or Med19 shRNA and cultured for one to five days. (b) BrdU incorporation assay was performed on cells treated with Med19 shRNA or negative control shRNA. (c) Representative colony of tongue cancer cells treated with control shRNA or Med19 shRNA. (d) Cells treated with Med19 shRNA made less clone number compared with control shRNA or blank control. (e) Fluorescence-activated cell sorting (FACS) analysis of cells phase of tongue cancer cells treated with negative control or Med19 shRNA. (f) Cells treated with Med19 shRNA showed higher cell numbers at the G1 phase. Mean values are derived from three independent experiments. Errors indicate standard deviation.